Key result
Preoperative plasma levels of ANGPT2 were elevated in patients with renal cell carcinoma compared to those with benign renal disease.
Why the study?
Do plasma levels of ANGPT2, TuM2PK, and VEGF correlate with pathological features and diagnosis in patients with renal cell carcinoma?
Observational (n=127)
No
Do plasma levels of ANGPT2, TuM2PK, and VEGF correlate with pathological features and diagnosis in patients with renal cell carcinoma?
Plasma ANGPT2 and TuM2PK levels are elevated in renal cell carcinoma and correlate with adverse pathological features such as tumor size and grade, suggesting potential utility as biomarkers.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: To assess pathological correlations and temporal trends of Angiopoietin-2 (ANGPT2), vascular endothelial growth factor (VEGF) and M2 Pyruvate kinase (TuM2PK), markers of tumor vascular development and metabolism, in patients with renal cell carcinoma (RCC). METHODS: We prospectively collected plasma samples from 89 patients who underwent surgical/ablative therapy for RCC and 38 patients with benign disease (nephrolithiasis, hematuria without apparent neoplastic origin, or renal cysts). In RCC patients, marker levels were compared between at least 1 preoperative and 1 postoperative time point generally 3 weeks after surgery. Marker temporal trends were assessed using the Wilcoxon sign-rank test. Plasma VEGF, ANGPT2, and TuM2PK levels were determined by ELISA and tested for association with pathological variables. RESULTS: Median age was comparable between groups. 83/89 (93%) of the cohort underwent surgical extirpation. 82% of the tumors were organ confined (T ≤ 2, N0). Only ANGPT2 exhibited significantly elevated preoperative levels in patients with RCC compared to benign disease (p = 0.046). Elevated preoperative levels of ANGPT2 and TuM2PK significantly correlated with increased tumor size and advanced grade (p < 0.05). Chromophobe RCC exhibited higher levels of ANGPT2 compared to other histologies (p < 0.05). A decline in marker level after surgery was not observed, likely due to the timing of the analyses. CONCLUSION: Our results suggest that ANGPT2 is a marker of RCC. Additionally, ANGPT2 and TuM2PK significantly correlated with several adverse pathological features. Further studies are needed to determine clinical applicability.
Answers are grounded in this paper and cite their sources.
Supports ANGPT2 as RCC biomarker candidate; hypothesis-generating and requires prospective validation before any clinical use.
No takes yet. Share an insight, caveat, or question.
Gayed et al. (2015) conducted an observational in Renal cell carcinoma (n=127). Renal cell carcinoma vs. Benign renal disease was evaluated on Preoperative plasma levels of ANGPT2 (p=0.046). Preoperative plasma levels of ANGPT2 were elevated in patients with renal cell carcinoma compared to those with benign renal disease.
Synapse has enriched 10 related papers. Consider them for comparative context: